Ansipastobart Biosimilar - Research Grade

Human

NT5E

>1mg/ml

IgG1 - lambda2

CHO Cells

Oleclumab Biosimilar - Research Grade (ICH5038), Uliledlimab Biosimilar - Research Grade (ICH5131), Mupadolimab Biosimilar - Research Grade (ICH5136), Dresbuxelimab Biosimilar - Research Grade (ICH5490), Uprevstobart Biosimilar - Research Grade (ICH5960)

https://www.imgt.org/mAb-DB/

ICH3002

P21589

Blue ice

Ansipastobart Biosimilar (Research Grade) is an unconjugated, non-therapeutic research analog of the originator antibody Ansipastobart, an anti-CD73 (NT5E) immunotherapeutic. It is supplied as a fully human IgG1, lambda2 immunoglobulin built around the CD73 target and is intended strictly for research use, not for clinical or diagnostic application. As a biosimilar reagent it recapitulates the target-binding specificity of the originator molecule, making it suitable as a reference standard, positive control, or tool antibody in studies of the adenosinergic pathway and CD73-directed immuno-oncology programs. This research-grade preparation is offered at low endotoxin (<1 EU/mg), which supports use in sensitive cell-based and functional assays where endotoxin contamination could confound results, and is available in bulk milligram to gram quantities to support screening, assay development, and comparability work. Because the originator targets human CD73, the product is oriented toward in-vitro and functional characterization rather than routine rodent in-vivo dosing. It provides a cost-effective, consistent alternative to therapeutic-lot material for laboratories characterizing CD73 biology, benchmarking novel anti-CD73 candidates, or establishing binding and neutralization assays. CD73 (ecto-5'-nucleotidase, encoded by NT5E; UniProt P21589) is a GPI-anchored, cell-surface enzyme, roughly 70 kDa, that typically functions as a homodimer and can also be shed into circulation in soluble form. It catalyzes the rate-limiting, terminal step of the extracellular purine cascade, dephosphorylating AMP to adenosine. Acting downstream of CD39, CD73 is the principal generator of extracellular adenosine, which engages adenosine receptors to suppress effector T-cell and NK-cell activity, promote regulatory phenotypes, and dampen anti-tumor immunity. CD73 is frequently upregulated on tumor cells and in the tumor microenvironment, correlating with immunosuppression and poor prognosis. Blocking CD73 enzymatic activity or its function is therefore an active immuno-oncology strategy intended to reduce adenosine accumulation and restore immune responses, often explored in combination with immune-checkpoint inhibitors.

5'-NT, 5'-deoxynucleotidase, Ecto-5'-nucleotidase, IMP-specific 5'-nucleotidase, Thymidylate 5'-phosphatase, 5'-nucleotidase, NT5, NTE

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks